Europe Antibiotics Market Size, Share & Trends Analysis Report by Drug Class (Cephalosporin, Penicillin), Type (Branded Antibodies, Generic Antibodies), Action Mechanism, Country, and Segment Forecasts, 2024-2030

The Europe antibiotics market size is anticipated to reach USD 13.7 billion by 2030 and is projected to grow at a CAGR of 3.28% from 2024 to 2030. The increasing urbanization and modernization result in people suffering from chronic disorders, which further drives the demand and sales of antibiotics in the region. In addition, the aged population in Europe has been demonstrated to be a primary factor driving the market growth.

The rising infectious diseases among healthcare personnel are prevalent as a result of hospital-acquired illnesses that involve excessive antibiotic usage. Thus, to trail the hospital procedure, the patients are required to stay in hospitals for a longer duration, which is evidenced to be a key reason for hospital-acquired infections and intake of antibiotics.

Europe Antibiotics Market Report Highlights

Based on drug class, the penicillin segment led the market with the largest revenue share of 25% in 2023, owing to its prominent application in treating various diseases, including diseases caused by streptococci, staphylococci, listeria, and clostridium. The cephalosporin segment is expected to grow at the fastest CAGR over the forecast period
Based on type, the generic antibiotics segment held the market with the largest revenue share of 81.0% in 2023, attributed to the reasonability of generic inventions and a supportive regulatory framework
Based on type, the branded antibiotics are anticipated to witness at the fastest CAGR over the forecast period, owing to the growing focus of key contributors to emphasize their product roles & distribution network
Europe dominated the market and held a considerable share in the global antibiotics market owing to factors such as growing numbers of patients with various infections and continuous trials conducted by pharmaceutical businesses
In September 2020, Shionogi & Co., Ltd. announced that it received FDA approval for a supplemental New Drug Application (sNDA), Fetroja (Cefiderocol). Antibiotics help treat hospital-acquired infectious pneumonia and ventilator-associated infective pneumonia
In 2023, LifeArc, Medicines Discovery Catapult, and Innovate UK founded PACE (Pathways to Antimicrobial Clinical Efficiency) to fund and support researchers involved in drug and diagnostics development to tackle antimicrobial resistance (AMR)

Chapter 1. Methodology and Scope

1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Drug class
1.2.2. Type
1.2.3. Action mechanism
1.2.4. Regional scope
1.2.5. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. Internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Drug class outlook
2.2.2. Type outlook
2.2.3. Action mechanism outlook
2.2.4. Regional outlook
2.3. Competitive Insights

Chapter 3. Europe Antibiotics Market Variables, Trends & Scope

3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.2. Market restraint analysis
3.3. Europe Antibiotics Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape

Chapter 4. Europe Antibiotics Market: Drug Class Estimates & Trend Analysis

4.1. Technology Market Share, 2023 & 2030
4.2. Segment Dashboard
4.3. Europe Antibiotics Market, by Drug Class Outlook
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
4.4.1. Cephalosporin
4.4.1.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.2. Penicillin
4.4.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.3. Fluoroquinolone
4.4.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.4. Macrolides
4.4.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.5. Carbapenems
4.4.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.6. Aminoglycosides
4.4.6.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.7. Sulfonamides
4.4.7.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.8. 7-ACA
4.4.8.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.9. Others
4.4.9.1. Market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Europe Antibiotics Market: Type Estimates & Trend Analysis

5.1. Type Market Share, 2023 & 2030
5.2. Segment Dashboard
5.3. Europe Antibiotics Market, by Type Outlook
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
5.4.1. Branded Antibiotics
5.4.1.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
5.4.2. Generic Antibiotics
5.4.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Europe Antibiotics Market: Action Mechanism Estimates & Trend Analysis

6.1. Action Mechanism Market Share, 2023 & 2030
6.2. Segment Dashboard
6.3. Europe Antibiotics Market, by Action Mechanism Outlook
6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
6.4.1. Cell Wall Synthesis Inhibitors
6.4.1.1. Market estimates and forecasts, 2018 to 2030 (USD million)
6.4.2. Protein Synthesis Inhibitors
6.4.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
6.4.3. DNA Synthesis Inhibitors
6.4.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
6.4.4. RNA Synthesis Inhibitors
6.4.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
6.4.5. Mycolic Acid Inhibitors
6.4.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
6.4.6. Others
6.4.6.1. Market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 7. Europe Antibiotics Market: County Estimates & Trend Analysis

7.1. Regional Market Share Analysis, 2023 & 2030
7.2. Regional Market Dashboard
7.3. Regional Market Snapshot
7.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
7.5. Europe
7.5.1. UK
7.5.1.1. Key country dynamics
7.5.1.2. Regulatory framework/ reimbursement structure
7.5.1.3. Competitive scenario
7.5.1.4. UK market estimates and forecasts, 2018 to 2030 (USD Million)
7.5.2. Germany
7.5.2.1. Key country dynamics
7.5.2.2. Regulatory framework/ reimbursement structure
7.5.2.3. Competitive scenario
7.5.2.4. Germany market estimates and forecasts, 2018 to 2030 (USD Million)
7.5.3. France
7.5.3.1. Key country dynamics
7.5.3.2. Regulatory framework/ reimbursement structure
7.5.3.3. Competitive scenario
7.5.3.4. France market estimates and forecasts, 2018 to 2030 (USD Million)
7.5.4. Italy
7.5.4.1. Key country dynamics
7.5.4.2. Regulatory framework/ reimbursement structure
7.5.4.3. Competitive scenario
7.5.4.4. Italy market estimates and forecasts, 2018 to 2030 (USD Million)
7.5.5. Spain
7.5.5.1. Key country dynamics
7.5.5.2. Regulatory framework/ reimbursement structure
7.5.5.3. Competitive scenario
7.5.5.4. Spain market estimates and forecasts, 2018 to 2030 (USD Million)
7.5.6. Norway
7.5.6.1. Key country dynamics
7.5.6.2. Regulatory framework/ reimbursement structure
7.5.6.3. Competitive scenario
7.5.6.4. Norway market estimates and forecasts, 2018 to 2030 (USD Million)
7.5.7. Sweden
7.5.7.1. Key country dynamics
7.5.7.2. Regulatory framework/ reimbursement structure
7.5.7.3. Competitive scenario
7.5.7.4. Sweden market estimates and forecasts, 2018 to 2030 (USD Million)
7.5.8. Denmark
7.5.8.1. Key country dynamics
7.5.8.2. Regulatory framework/ reimbursement structure
7.5.8.3. Competitive scenario
7.5.8.4. Denmark market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

8.1. Recent Developments & Impact Analysis, By Key Market Participants
8.2. Company/Competition Categorization
8.3. Vendor Landscape
8.3.1. List of key distributors and channel partners
8.3.2. Key customers
8.4. Company Profiles
8.4.1. AbbVie, Inc.
8.4.1.1. Company overview
8.4.1.2. Financial performance
8.4.1.3. Product benchmarking
8.4.1.4. Strategic initiatives
8.4.2. Pfizer Inc.
8.4.2.1. Company overview
8.4.2.2. Financial performance
8.4.2.3. Product benchmarking
8.4.2.4. Strategic initiatives
8.4.3. Novartis AG
8.4.3.1. Company overview
8.4.3.2. Financial performance
8.4.3.3. Product benchmarking
8.4.3.4. Strategic initiatives
8.4.4. Merck & Co., Inc.
8.4.4.1. Company overview
8.4.4.2. Financial performance
8.4.4.3. Product benchmarking
8.4.4.4. Strategic initiatives
8.4.5. Teva Pharmaceutical Industries Ltd.
8.4.5.1. Company overview
8.4.5.2. Financial performance
8.4.5.3. Product benchmarking
8.4.5.4. Strategic initiatives
8.4.6. Lupin Pharmaceuticals, Inc.
8.4.6.1. Company overview
8.4.6.2. Financial performance
8.4.6.3. Product benchmarking
8.4.6.4. Strategic initiatives
8.4.7. Viatris, Inc.
8.4.7.1. Company overview
8.4.7.2. Financial performance
8.4.7.3. Product benchmarking
8.4.7.4. Strategic initiatives
8.4.8. Melinta Therapeutics LLC
8.4.8.1. Company overview
8.4.8.2. Financial performance
8.4.8.3. Product benchmarking
8.4.8.4. Strategic initiatives
8.4.9. Cipla, Inc.
8.4.9.1. Company overview
8.4.9.2. Financial performance
8.4.9.3. Product benchmarking
8.4.9.4. Strategic initiatives
8.4.10. Shionogi & Co., Ltd.
8.4.10.1. Company overview
8.4.10.2. Financial performance
8.4.10.3. Product benchmarking
8.4.10.4. Strategic initiatives
8.4.11. KYORIN Pharmaceutical Co., Ltd.
8.4.11.1. Company overview
8.4.11.2. Financial performance
8.4.11.3. Product benchmarking
8.4.11.4. Strategic initiatives
8.4.12. GSK Plc
8.4.12.1. Company overview
8.4.12.2. Financial performance
8.4.12.3. Product benchmarking
8.4.12.4. Strategic initiatives
8.4.13. Nabriva Therapeutics PLC
8.4.13.1. Company overview
8.4.13.2. Financial performance
8.4.13.3. Product benchmarking
8.4.13.4. Strategic initiatives

List of Tables

Table 1 List of abbreviations
Table 2 Europe antibiotics market, by region, 2018 - 2030 (USD Million)
Table 3 Europe antibiotics market, by drug class, 2018 - 2030 (USD Million)
Table 4 Europe antibiotics market, by type, 2018 - 2030 (USD Million)
Table 5 Europe antibiotics market, by action mechanism, 2018 - 2030 (USD Million)
Table 6 Germany antibiotics market, by drug class, 2018 - 2030 (USD Million)
Table 7 Germany antibiotics market, by type, 2018 - 2030 (USD Million)
Table 8 Germany antibiotics market, by action mechanism, 2018 - 2030 (USD Million)
Table 9 UK antibiotics market, by drug class, 2018 - 2030 (USD Million)
Table 10 UK antibiotics market, by type, 2018 - 2030 (USD Million)
Table 11 UK antibiotics market, by action mechanism, 2018 - 2030 (USD Million)
Table 12 France antibiotics market, by drug class, 2018 - 2030 (USD Million)
Table 13 France antibiotics market, by type, 2018 - 2030 (USD Million)
Table 14 France antibiotics market, by action mechanism, 2018 - 2030 (USD Million)
Table 15 Italy antibiotics market, by drug class, 2018 - 2030 (USD Million)
Table 16 Italy antibiotics market, by type, 2018 - 2030 (USD Million)
Table 17 Italy antibiotics market, by action mechanism, 2018 - 2030 (USD Million)
Table 18 Spain antibiotics market, by drug class, 2018 - 2030 (USD Million)
Table 19 Spain antibiotics market, by type, 2018 - 2030 (USD Million)
Table 20 Spain antibiotics market, by action mechanism, 2018 - 2030 (USD Million)
Table 21 Denmark antibiotics market, by drug class, 2018 - 2030 (USD Million)
Table 22 Denmark antibiotics market, by type, 2018 - 2030 (USD Million)
Table 23 Denmark antibiotics market, by action mechanism, 2018 - 2030 (USD Million)
Table 24 Sweden antibiotics market, by drug class, 2018 - 2030 (USD Million)
Table 25 Sweden antibiotics market, by type, 2018 - 2030 (USD Million)
Table 26 Sweden antibiotics market, by action mechanism, 2018 - 2030 (USD Million)
Table 27 Norway antibiotics market, by drug class, 2018 - 2030 (USD Million)
Table 28 Norway antibiotics market, by type, 2018 - 2030 (USD Million)
Table 29 Norway antibiotics market, by action mechanism, 2018 - 2030 (USD Million)

List of Figures

Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Europe antibiotics market: market outlook
Fig. 9 Tumor ablation competitive insights
Fig. 10 Parent market outlook
Fig. 11 Related/ancillary market outlook
Fig. 12 Penetration and growth prospect mapping
Fig. 13 Europe antibiotics market driver impact
Fig. 14 Europe antibiotics market restraint impact
Fig. 15 Europe antibiotics market: Drug class movement analysis
Fig. 16 Europe antibiotics market: Drug class outlook and key takeaways
Fig. 17 Cephalosporin market estimates and forecast, 2018 - 2030
Fig. 18 Penicillin estimates and forecast, 2018 - 2030
Fig. 19 Fluoroquinolone market estimates and forecast, 2018 - 2030
Fig. 20 Macrolides ablation estimates and forecast, 2018 - 2030
Fig. 21 Carbapenems market estimates and forecast, 2018 - 2030
Fig. 22 Aminoglycosides market estimates and forecast, 2018 - 2030
Fig. 23 Sulfonamides market estimates and forecast, 2018 - 2030
Fig. 24 7-ACA market estimates and forecast, 2018 - 2030
Fig. 25 Others estimates and forecast, 2018 - 2030
Fig. 26 Europe antibiotics Market: Drug class movement Analysis
Fig. 27 Europe antibiotics market: Drug class outlook and key takeaways
Fig. 28 Cephalosporin market estimates and forecasts, 2018 - 2030
Fig. 29 Penicillin market estimates and forecasts,2018 - 2030
Fig. 30 Fluoroquinolone market estimates and forecasts, 2018 - 2030
Fig. 31 Macrolides market estimates and forecasts, 2018 - 2030
Fig. 32 Carbapenems market estimates and forecasts, 2018 - 2030
Fig. 33 Aminoglycosides market estimates and forecasts, 2018 - 2030
Fig. 34 Sulfonamides market estimates and forecasts, 2018 - 2030
Fig. 35 7-ACA market estimates and forecasts, 2018 - 2030
Fig. 36 Others market estimates and forecasts, 2018 - 2030
Fig. 37 Europe antibiotics market: Type movement analysis
Fig. 38 Europe antibiotics market: type outlook and key takeaways
Fig. 39 Branded antibiotics market estimates and forecasts, 2018 - 2030
Fig. 40 Generic antibiotics market estimates and forecasts, 2018 - 2030
Fig. 41 Europe antibiotics Market: Action mechanism movement Analysis
Fig. 42 Europe antibiotics market: Action mechanism outlook and key takeaways
Fig. 43 Cell wall synthesis inhibitors market estimates and forecasts, 2018 - 2030
Fig. 44 Protein synthesis inhibitors market estimates and forecasts, 2018 - 2030
Fig. 45 DNA synthesis inhibitors market estimates and forecasts, 2018 - 2030
Fig. 46 RNA synthesis inhibitors market estimates and forecasts, 2018 - 2030
Fig. 47 Mycolic acid inhibitors market estimates and forecasts, 2018 - 2030
Fig. 48 Others market estimates and forecasts, 2018 - 2030
Fig. 49 Europe antibiotics market: Regional movement analysis
Fig. 50 Europe antibiotics market: Regional outlook and key takeaways
Fig. 51 Europe antibiotics market share and leading players
Fig. 52 Europe market share and leading players
Fig. 53 Europe SWOT
Fig. 54 Europe
Fig. 55 Europe market estimates and forecasts, 2018 - 2030
Fig. 56 UK
Fig. 57 UK market estimates and forecasts, 2018 - 2030
Fig. 58 Germany
Fig. 59 Germany market estimates and forecasts, 2018 - 2030
Fig. 60 France
Fig. 61 France market estimates and forecasts, 2018 - 2030
Fig. 62 Italy
Fig. 63 Italy market estimates and forecasts, 2018 - 2030
Fig. 64 Spain
Fig. 65 Spain market estimates and forecasts, 2018 - 2030
Fig. 66 Denmark
Fig. 67 Denmark market estimates and forecasts, 2018 - 2030
Fig. 68 Sweden
Fig. 69 Sweden market estimates and forecasts, 2018 - 2030
Fig. 70 Norway
Fig. 71 Norway market estimates and forecasts, 2018 - 2030

Companies Mentioned

AbbVie, Inc.
Pfizer Inc.
Novartis AG
Merck & Co., Inc.
Teva Pharmaceutical Industries Ltd.
Lupin Pharmaceuticals, Inc.
Viatris, Inc.
Melinta Therapeutics LLC
Cipla, Inc.
Shionogi & Co., Ltd.
KYORIN Pharmaceutical Co., Ltd.
GSK Plc
Nabriva Therapeutics PLC

Methodology

LOADING...

Table Information

Report Attribute	Details
No. of Pages	80
Published	March 2024
Forecast Period	2023 - 2030
Estimated Market Value ( USD ) in 2023	$ 10.9 Billion
Forecasted Market Value ( USD ) by 2030	$ 13.7 Billion
Compound Annual Growth Rate	3.2%
Regions Covered	Europe
No. of Companies Mentioned	13

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€5852EUR$5,950USD£4,823GBP
1 - 5 USER LICENSE PDF	The product is a PDF.	This is a 1-5 user license, allowing up to five users have access to the product.	€6835EUR$6,950USD£5,634GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€8802EUR$8,950USD£7,255GBP

Europe Antibiotics Market Report Highlights

Table of Contents

Companies Mentioned

Methodology

Table Information

Related Topics

Related Reports

Antibacterial Drugs Market Report 2024-2034

Antibiotics: World Trade, Markets and Competitors

Antibiotics Market Size, Share & Trends Analysis Report by Action Mechanism (Cell Wall Synthesis Inhibitors, RNA Synthesis Inhibitors), Drug Class (Penicillin, Cephalosporin), Type (Branded, Generic), and Segment Forecasts, 2024-2030

Cephalosporin Drugs Market by Generation of Cephalosporin, Drug Administration, Prescription Type, Application - Global Forecast 2025-2030

Antibiotic Drugs Market (2024 Edition): Analysis By Drug Class (Cephalosporin, Penicillin, Macrolides, Fluoroquinolone, Others), Spectrum (Broad, Narrow), By Indication, By Region, By Country: Market Insights and Forecast (2019-2029)